全文获取类型
收费全文 | 3051篇 |
免费 | 184篇 |
国内免费 | 52篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 2篇 |
基础医学 | 10篇 |
口腔科学 | 2篇 |
临床医学 | 24篇 |
内科学 | 33篇 |
皮肤病学 | 5篇 |
神经病学 | 5篇 |
特种医学 | 32篇 |
外科学 | 22篇 |
综合类 | 452篇 |
预防医学 | 26篇 |
眼科学 | 3篇 |
药学 | 1892篇 |
中国医学 | 772篇 |
肿瘤学 | 5篇 |
出版年
2024年 | 42篇 |
2023年 | 106篇 |
2022年 | 136篇 |
2021年 | 207篇 |
2020年 | 169篇 |
2019年 | 252篇 |
2018年 | 220篇 |
2017年 | 200篇 |
2016年 | 166篇 |
2015年 | 89篇 |
2014年 | 188篇 |
2013年 | 147篇 |
2012年 | 212篇 |
2011年 | 188篇 |
2010年 | 132篇 |
2009年 | 94篇 |
2008年 | 100篇 |
2007年 | 116篇 |
2006年 | 125篇 |
2005年 | 61篇 |
2004年 | 76篇 |
2003年 | 61篇 |
2002年 | 40篇 |
2001年 | 45篇 |
2000年 | 28篇 |
1999年 | 20篇 |
1998年 | 9篇 |
1997年 | 14篇 |
1996年 | 14篇 |
1995年 | 7篇 |
1994年 | 7篇 |
1993年 | 4篇 |
1992年 | 5篇 |
1991年 | 4篇 |
1990年 | 1篇 |
1986年 | 1篇 |
1985年 | 1篇 |
排序方式: 共有3287条查询结果,搜索用时 31 毫秒
41.
42.
四神止泻胶囊的制备及其质量控制 总被引:1,自引:0,他引:1
目的:制备四神止泻胶囊,并建立质量控制方法。方法:采用薄层色谱法鉴别肉豆蔻、五味子和吴茱萸三味药材,高效液相色谱法测定成品中补骨脂素和异补骨脂素的含量。结果:肉豆蔻、五味子和吴茱萸薄层色谱斑点清晰;成品三批中补骨脂素和异补骨脂素含量稳定。结论:四神止泻胶囊制备工艺合理,质量控制方法可行。 相似文献
43.
目的:建立生化产复康胶囊中阿魏酸的含量测定方法。方法:采用高效液相色谱法,以kromasil C18柱为固定相,乙睛-0.085%磷酸溶液(17:83)为流动相,检测波长315nm,流速1.0ml/min,柱温35℃。结果:阿魏酸在0.076~0.228ug(r=0.9999)范围内线性关系良好,平均回收率为100.25%、RSD为1.84%。结论:本方法简便,准确,重现性好,可用于测定生化产复康胶囊中阿魏酸的含量。 相似文献
44.
45.
46.
47.
目的:建立复合氨基酸胶囊中5种水溶性维生素的含量测定方法.方法:采用高效液相色谱法,用乙腈与庚烷磺酸钠-磷酸钠的水溶液(pH=3.0)为流动相,流速1.0ml·min-1,色谱柱为C18(4.6×250mm,5μm),柱温40℃,检测波长为280nm,进样量为20μl.结果:维生素Bl、维生素B2、维生素B6、维生素C和烟酰胺分别在24.7~75.2μg·ml-1、15.0~44.9μg·ml-1、12.2~37.5μg·ml-1、99.2~299.9μg·ml-1和100.3~300.9μg·ml-1范围内呈线性关系,相关系数均为1.000,平均回收率均在100%±2%范围以内.RSD分别为0.19%、0.26%、0.46%、1.17%和0.52%.结论:本方法准确,简便,快捷,可以同时测定复合氨基酸胶囊中维生素B1、维生素B2、维生素B6、维生素C和烟酰胺的含量. 相似文献
48.
《Ultrasound in medicine & biology》2016,42(10):2391-2400
Our purpose was to evaluate the feasibility of using ultrasonographic criteria of thyroid capsular continuity and tumor contour to differentiate macroscopic extra-thyroidal extension (ETE) from microscopic ETE, as well as non-ETE from ETE. On ultrasonography, we evaluated thyroid capsular continuity (C0 = continuous, C1 = discontinuous, C2 = invisible), and thyroid tumor contour (P0 = in normal parenchyma, P1 = abutting, P2 = bulging), which were grouped into type 1–9 classifications. Either C1–2 or P1–2 was more prevalent in ETE than non-ETE. C1 and P2 tended to be associated with macroscopic ETE, whereas C0 and P1 were significantly associated with microscopic ETE. Types 6, 8 and 9 were more likely to have ETE than non-ETE; type 6 (C1 P2) and type 9 (C2 P2) were significantly associated with macroscopic ETE, whereas type 8 (C2 P1) was associated more with microscopic ETE. Macroscopic and microscopic ETE, as well as non-ETE and ETE, can be differentiated using these pre-operative ultrasonographic criteria. 相似文献
49.
《Current medical research and opinion》2013,29(7):371-380
SummaryObjective:The objective of the study was to investigate the effectiveness and safety of Metadate® CD (methylphenidate HCl, USP) Extended Release Capsules in the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD), in actual clinical practice.Method:This was a multicenter, open-label, postmarketing study. Eligible patients were aged 6-17 with a diagnosis of ADHD and receiving either no treatment or maintenance treatment with another approved methylphenidate (MPH) product. Metadate® CD was administered once daily for 3 weeks, titrated against reported and observed symptoms. Clinical Global Impression (CGI) scores at Week 3 were used for the primary efficacy evaluation. Patient treatment satisfaction was determined by questionnaire at the final evaluation visit. Safety was assessed through adverse event reporting, laboratory tests and vital sign measurements.Results: Overall, of the 308 patients in the Intent-To-Treat population, the majority (65%) demonstrated a positive response to Metadate® CD (defined as CGI Global Improvement rating of very much or much improved). In addition, patients previously treated with immediate-release or extended-release tablet formulations of MPH were successfully converted to Metadate® CD at a comparable dose. Most patients (87%) were very satisfied or moderately satisfied with study treatment, and among previously treated patients, 71% rated Metadate® CD as much better or better than their previous MPH treatment. Adverse events were consistent with current FDA-approved product labeling for Metadate® CD.Conclusions: Metadate® CD is effective and well-tolerated in actual clinical use for ADHD. 相似文献
50.
目的:探讨补中益气颗粒联合多糖铁复合物治疗妊娠期缺铁性贫血(IDA)的临床疗效。方法:将120例妊娠期IDA患者按照随机数字表法分为2组,每组60例。对照组给予多糖铁复合物治疗,研究组给予补中益气颗粒联合多糖铁复合物治疗,均用药4周。比较2组治疗前后红细胞(RBC)计数、血红蛋白(Hb)含量、平均红细胞血红蛋白含量(MCH)、血清铁(SI)、血清铁蛋白(SF)、铁调素和可溶性转铁蛋白受体(sTfR),以及2组治疗总有效率、不良反应和不良妊娠结局发生率。结果:治疗后研究组RBC、Hb、MCH、SI和SF均高于对照组,铁调素和sTfR低于对照组,治疗总有效率高于对照组,差异均有统计学意义(均P<0.05)。2组不良反应发生率和不良妊娠结局发生率差异无统计学意义(P>0.05)。结论:补中益气颗粒联合多糖铁复合物可有效改善铁代谢,治疗妊娠期IDA效果显著,安全性较好。 相似文献